TY - JOUR
T1 - Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited
T2 - An ongoing story
AU - Caminero, Ana
AU - Comabella, Manuel
AU - Montalban, Xavier
N1 - © Copyright 2011 Elsevier B.V., All rights reserved
PY - 2011/5
Y1 - 2011/5
N2 - Tumor necrosis factor alpha (TNF-α) is a cytokine with pleiotropic actions that can be present both as a transmembrane protein and soluble cytokine (sTNF). Both ligands interact with two different receptors, TNFR1 and TNFR2, which mediate their biological effects. TNF-α is involved in the pathogenesis of multiple sclerosis (MS), however, administration of anti-TNF-α agents to MS patients has been associated with increased disease activity. Insomuch as TNFR1 mediates demyelination and TNFR2 remyelination, it could be hypothesized that anti-TNF-α agents which selectively inhibit sTNF or signals from TNFR1 could be effective in treating MS.
AB - Tumor necrosis factor alpha (TNF-α) is a cytokine with pleiotropic actions that can be present both as a transmembrane protein and soluble cytokine (sTNF). Both ligands interact with two different receptors, TNFR1 and TNFR2, which mediate their biological effects. TNF-α is involved in the pathogenesis of multiple sclerosis (MS), however, administration of anti-TNF-α agents to MS patients has been associated with increased disease activity. Insomuch as TNFR1 mediates demyelination and TNFR2 remyelination, it could be hypothesized that anti-TNF-α agents which selectively inhibit sTNF or signals from TNFR1 could be effective in treating MS.
KW - Anti-TNF-α
KW - Multiple sclerosis
KW - Proinflammatory cytokines
KW - TNF-α
UR - https://www.scopus.com/pages/publications/79955646245
U2 - 10.1016/j.jneuroim.2011.03.004
DO - 10.1016/j.jneuroim.2011.03.004
M3 - Review article
C2 - 21474190
AN - SCOPUS:79955646245
SN - 0165-5728
VL - 234
SP - 1
EP - 6
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
IS - 1-2
ER -